Extended Data Fig. 4: Differential genomic and prognostic features of KRAS variants: additional insights.

a, Bubble chart of co-occurring KRAS mutations. Number and bubble size indicate the prevalence of a given combination, and number in parentheses is the prevalence of the mutation in the overall cohort. b, Purity-adjusted variant allele frequency (VAF) of KRAS mutations by tumor, ordered by difference in VAF. Please note the 14 tumors shown here are excluded from Fig. 4. c, Prevalence of sex, genetic ancestry, age at diagnosis and smoking status by KRAS variant. Dotted line for age shows overall median. P value denotes two-sided Fisher’s exact test. Boxes for age represent the 25th, 50th (median) and 75th percentiles. Whiskers represent the minimum and maximum values, no further than 1.5× the interquartile range (IQR) from the respective upper and lower quartiles, with points beyond this range plotted individually. d, Prevalence of WGD by KRAS variant (n = 1,150); prevalence of KRAS allelic imbalance and KRAS allele selection state by KRAS variant among diploid tumors (n = 927). e,f, Progression-free survival (PFS) differences between first-line standard-of-care treatments across the different KRAS variant groups. e, Kaplan–Meier curves for PFS differences between FOLFIRINOX (5-FU) and gemcitabine for KRAS G12D, G12V and G12R. P values represent statistical comparison of univariate Kaplan–Meier curves by log-rank test. f, Multivariable Cox proportional hazards model for e. P values are nominal two-sided P values from the Cox regression model. Error bars represent 95th percentile binomial CIs around the mean for c and d.